Benzinga | Nov 2, 2021 10:56AM EDT

Mizuho Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $103

Mizuho analyst Vamil Divan maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and raises the price target from $99 to $103.